Sulfonylureas as 2nd-line T2DM therapy tied to higher event risk

July 24, 2018

(HealthDay)—Sulfonylureas as second-line drugs for type 2 diabetes are associated with an increased risk of cardiovascular and hypoglycemic events compared with remaining on metformin monotherapy or adding to metformin therapy, according to a study published online July 18 in The BMJ.

Antonios Douros, M.D., Ph.D., from Jewish General Hospital in Montreal, and colleagues assessed whether adding or switching to sulfonylureas is associated with an increased risk of cardiovascular and hypoglycemic events. Patients adding or switching to sulfonylureas (25,699 subjects) were matched in a 1-to-1 ratio with those remaining on monotherapy based on multiple factors, including hemoglobin A1c and number of previous metformin prescriptions.

The researchers found that over a mean follow-up of 1.1 years, sulfonylureas were associated with an increased risk of (hazard ratio [HR], 1.26; 95 percent confidence interval [CI], 1.01 to 1.56), all-cause mortality (HR, 1.28; 95 percent CI, 1.15 to 1.44), and severe hypoglycemia (HR, 7.6; 95 percent CI, 4.64 to 12.44) versus continuing metformin . Switching to sulfonylureas was associated with an increased risk of myocardial infarction (HR, 1.51; 95 percent CI, 1.03 to 2.24) and all-cause mortality (HR, 1.23; 95 percent CI, 1.0 to 1.5) compared with adding sulfonylureas. There were no differences observed for ischemic stroke, cardiovascular death, or severe hypoglycemia.

"Continuing metformin when introducing sulfonylureas appears to be safer than switching," the authors write.

One author disclosed ties to pharmaceutical companies including Boehringer Ingelheim, which provided funding for the study.

Explore further: Switching to certain antidiabetic drugs linked to increased risk of major complications

More information: Abstract/Full Text
Editorial

Related Stories

Switching to certain antidiabetic drugs linked to increased risk of major complications

July 18, 2018
For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today.

CVD risk similar for metformin + insulin or sulfonylureas

July 20, 2015
(HealthDay)—For patients with type 2 diabetes, the risk of myocardial infarction (MI) or stroke is similar for treatment with insulin or sulfonylureas in combination with metformin, according to a study published online ...

Sulfonylureas up cardio events versus metformin

November 7, 2012
(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of ...

First-line metformin use for DM up; sulfonylurea use down

November 19, 2017
(HealthDay)—Among patients with type 2 diabetes initiating antidiabetes drugs (ADDs), first-line use of metformin has increased since 2005, while sulfonylureas have remained the most popular second-line agent, according ...

Metformin use doesn't cut incidence of bladder cancer

February 11, 2014
(HealthDay)—For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study published online Feb. 4 in Diabetes Care.

CV risk not significantly different for GLP-1 receptor agonists

April 13, 2016
(HealthDay)—There are no significant differences in occurrence of cardiovascular disease (CVD) tied to treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) compared with dipeptidyl peptidase-4 inhibitors ...

Recommended for you

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

New therapeutic avenue for type 2 diabetes

December 6, 2018
Restoring the action of insulin is one of the keys to fighting type 2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Université de Toulouse) are ...

Subtype of immune B cells can delay type 1 diabetes onset in mice

December 6, 2018
A team of researchers at Baylor College of Medicine and the University of Michigan Medical School reports today in the JCI Insight that a subset of immune B cells, known as CD19+IgM+ B cells, can delay the onset of type 1 ...

Is the pancreas regeneration debate settled? An original theory renewed

December 5, 2018
A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.